Advances in the Diagnosis and Treatment of Neuroblastoma: Paradigm for Precision Medicine
Objectives and Disclosures
Participants will be able to:
- Assess the clinical presentations, diagnostic workup and risk stratification approach to neuroblastoma in children.
- Outline current and emerging treatment strategies.
- Analyze how clinical features, tumor biology/biomarkers, genetics and social determinants inform prognosis and treatment decision-making.
Seattle Children’s CME Speaker and Planners disclose they have no relevant financial relationships.
Meredith Irwin, MD
Paediatrician-in-Chief, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada; Chair, Department of Paediatrics, Temerty Faculty of Medicine and Professor, Departments of Paediatrics, Medical Biophysics, and Laboratory Medicine & Pathobiology, University of Toronto
CME Credit
Seattle Children’s is accredited by the Washington State Medical Association CME Accreditation Committee to sponsor continuing medical education for physicians.
Seattle Children’s designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 1 hour of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Videos are available for only one year after posting.
If you wish to receive Category I CME credit for viewing this Provider Grand Rounds session, please complete the evaluation form. Upon completion of the form you will receive an auto-reply email that will serve as the only confirmation of your CME credit. Please keep the email for your records.
Provider News
The monthly Provider News email provides updates for healthcare professionals about programs and services at Seattle Children’s.
Want to receive Provider News via email? Subscribe now.